June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Tear proteome provides basis for patient stratification after switching to a unpreserved glaucoma medication
Author Affiliations & Notes
  • Antti Jylhä
    Ophthalmology, Medical School, University of Tampere, Tampere, Pirkanmaa, Finland
  • Janika Nattinen
    Ophthalmology, Medical School, University of Tampere, Tampere, Pirkanmaa, Finland
    BioMediTech, University of Tampere, Tampere, Pirkanmaa, Finland
  • Ulla Aapola
    Ophthalmology, Medical School, University of Tampere, Tampere, Pirkanmaa, Finland
  • Matti Nykter
    BioMediTech, University of Tampere, Tampere, Pirkanmaa, Finland
  • Roger W. Beuerman
    Singapore Eye Research Institute, Singapore, Singapore
  • Hannu M T Uusitalo
    Ophthalmology, Medical School, University of Tampere, Tampere, Pirkanmaa, Finland
    TAYS Eye Center, Tampere University Hospital, Tampere, Finland
  • Footnotes
    Commercial Relationships   Antti Jylhä, None; Janika Nattinen, None; Ulla Aapola, None; Matti Nykter, None; Roger Beuerman, Allergan (C); Hannu Uusitalo, Santen (F)
  • Footnotes
    Support  TEKES 40087/12
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 2115. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Antti Jylhä, Janika Nattinen, Ulla Aapola, Matti Nykter, Roger W. Beuerman, Hannu M T Uusitalo; Tear proteome provides basis for patient stratification after switching to a unpreserved glaucoma medication. Invest. Ophthalmol. Vis. Sci. 2017;58(8):2115.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Glaucoma patients commonly experience adverse events due to long-term use of benzalkonium chloride (BAK) preserved glaucoma medication. It was hypothesized that the tear proteome would reflect the mechanisms involved in ocular surface adverse reactions such as inflammation. In order to study this concept, the tear proteome was analyzed in patients before and over one year period after switching from a preserved to an unpreserved prostaglandin drug.

Methods : Study consisted of 28 patients and 5 visits: screening/baseline visit and visits at 1.5, 3, 6 and 12 months after the medication switch from preserved latanoprost (Xalatan®) to preservative-free tafluprost (Taflotan®). Clinical evaluation and tear collection using Schirmer’s strips were performed during each visit. Relative quantification of tear proteins was done by NanoLC-TripleMSTOF using SWATH. Statistical and MS data analysis were performed with extensive software by Sciex, R software and Ingenuity pathway analysis (IPA).

Results : SWATH library for 978 proteins was created and 785 proteins were relatively quantified in each sample. We compared protein expression data between the visits and identified 3 distinctive protein clusters with high reliability (p≥0.001). One of the clusters consisted of beneficial (lacrimal gland secreted proteins) ocular surface biomarkers, e.g. LYZ, PROL1 and various cystatins. Another two clusters included well-known inflammation related proteins such as ALB, TF and S100A8 and C3, ENO1 and S100A9. Further analysis of the clusters revealed 41 differentially expressed proteins (adjusted p-value < 0.05). Pathway analysis identified ‘inflammation of organ’ as the most enriched function term (p-value = 1.20E-05).

Conclusions : Proteomic analysis stratified patients into three different groups. Two of them showed improvement of tear protein profile while one group showed increase in inflammatory related proteins. In the future, selected protein profiles could be used for the prediction of best therapeutic options for glaucoma patient.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×